Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
WX390 tablets in advanced solid tumors with PIK3CA alterations
CTR20210917Phase 2Active
- Sponsor
- Cisen Pharmaceutical Co., Ltd.
- Start
- Jun 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of WXFL10030390 in Nonhematologic neoplasms, sponsored by Cisen Pharmaceutical Co., Ltd.. Started Jun 2021; status: active.
02
Drugs
WXFL10030390
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on CTR20210917.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20210917.